At a glance
- Originator National Cancer Institute (USA); Research Triangle Park Laboratories
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Sep 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)